EXtendedAnalysis for Cancer Treatment

Malignant Solid Tumor Clinical Trial

Official title:

EXACT: EXtendedAnalysis for Cancer Treatment A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02999750
• Other study ID #: EXACT
• Status: Active, not recruiting
• Phase: N/A
• First received: December 7, 2016
• Last updated: December 16, 2016
• Start date: October 2013
• Est. completion date: October 2017

Study information

• Verified date: December 2016
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food Safety
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to prospectively validate treatment benefit of an individualized treatment concept based on molecular profiling (MP) from paraffin-embedded tumor tissue sections obtained before the start of treatment (real time biopsy).

Description:

The treatment concept will be considered to be of clinical benefit for the individual patient if a progression-free survival (PFS) ratio (PFS on MP-based therapy / best PFS achieved by prior therapy) will be > 1.0 thus generating a patient cohort with this very property. Thereby, the null hypothesis (that ≤ 40 % of this patient population would have a PFS ratio of > 1.0) will be evaluated with each patient being his own control. For tumor types with high numbers of patients per cohort, the overall response rate (ORR) will be evaluated.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 55
• Est. completion date: October 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

Consenting patients of >19 years with advanced cancer fulfilling the criteria of having:

• an advanced malignancy with metastatic spread refractory to conventional treatment

• a life expectancy of >4 months,

• the possibility to access and biopsy tumour material within 4 weeks before onset of individualized treatment,

• a malignancy amenable to further treatment options with either cytotoxic drugs, tyrosine kinase inhibitors, monoclonal antibodies or related molecules with anti-proliferative potential to cancer cells, as assessed by the ex vivo analysis and a likelihood of treatment response according to the mathematical model (all outlined in detail above),

• agreed to participate by their signature on an informed consent form are eligible.

Exclusion Criteria:

• Presence of further treatment options, as defined by NCCN guidelines which are available in Austria representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence.

• No fresh and viable tumor material available.

• Current use of therapeutic warfarin.

• Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.

• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.

• A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.

• A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.

• History of other malignancy. Subjects who have been disease-free for 5 years or those with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

• Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol)

• unwillingness or inability to follow the procedures required in the protocol.

• pregnant or lactating females.

• History of alcohol or drug abuse within 6 months prior to screening.

• No informed consent available.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malignant Solid Tumor

Intervention

Other:
• individual therapy
Patient will be treated with individual therapy.

Locations

Country	Name	City	State
Austria	AKH Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Use of real time biopsy to establish an individual molecular profile by using next generation sequencing	pathological examination (includes genetic and target expression profiling, and drug sensitivity screening) to rank treatment options and the potential correlation between treatment response and progression free survival	2 years	Yes